CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.
Paret C, Simon P, Vormbrock K, Bender C, Kölsch A, Breitkreuz A, Yildiz Ö, Omokoko T, Hubich-Rau S, Hartmann C, Häcker S, Wagner M, Roldan DB, Selmi A, Türeci Ö, Sahin U.
Paret C, et al. Among authors: tureci o.
Oncotarget. 2015 Sep 22;6(28):25356-67. doi: 10.18632/oncotarget.4516.
Oncotarget. 2015.
PMID: 26327325
Free PMC article.